SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Multiple Dianthus Therapeutics insiders, including CEO Marino and GC…

Dianthus Therapeutics, Inc. /DE/ · CLUSTER filed Aug 11, 2026 at 17:15 ET

At the news

NEUTRALIMPACT 4/10

CLUSTER filed Aug 11, 2026 at 17:15 ET

Multiple Dianthus Therapeutics insiders, including CEO Marino and GC Veness, executed open-market sales totaling $3.15M over a 7-day window, with $1.12M (CEO) and $1.78M (GC) concentrated on a single day. The sales are likely liquidity-driven following vesting and option exercises (non-cash derivatives), but the CEO's involvement and total value relative to the $6.5B market cap (0.048%) suggests routine portfolio diversification rather than a bearish signal.

  • 4 insiders sold a total of ~$3.15M in open-market transactions from Aug 7-10, 2026.
  • CEO Marino sold 10.4K shares at $107.49 for $1.12M on Aug 7.
  • GC Veness sold 16.2K shares at $110.38 for $1.78M on Aug 10.
  • Total insider sales represent 0.048% of $6.5B market cap, well below any material threshold.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access